Primary medication treatment of AD (secondary prevention)
Cholinesterase inhibitors are the mainstay of therapy
- Two drugs currently on the market (Aricept and Exelon); one about to be launched (Reminyl)
- Though some patients experience immediate improvement, most prominent effect is cognitive stabilization
- Functional improvement follows cognitive enhancement or stabilization
- Positive effects of these agents appear to be sustained